Prothena Corporation plc - Ordinary Shares (PRTA) News
Filter PRTA News Items
PRTA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PRTA News Highlights
- PRTA's 30 day story count now stands at 13.
- Over the past 26 days, the trend for PRTA's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
- The most mentioned tickers in articles about PRTA are BEAT, AXSM and BMY.
Latest PRTA News From Around the Web
Below are the latest news stories about PROTHENA CORP PUBLIC LTD CO that investors may wish to consider to help them evaluate PRTA as an investment opportunity.
Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth StocksBuild and maintain your watch list with the latest news and analysis of the market's top-rated growth stocks. |
FOCUS-Researchers return to Alzheimer's vaccines, buoyed by recent drug successBreakthrough Alzheimer’s treatments that remove toxic proteins from the brain have revived interest in vaccines to treat the memory-robbing disease, potentially offering a cheaper, easy-to-administer option for millions of people, according to interviews with 10 scientists and company executives. Clinical trials are underway or completed for at least seven Alzheimer’s vaccines designed to harness the immune system to rid the brain of the disease-related proteins beta amyloid or tau, a review of the U.S. government’s ClinicalTrials.gov database found. The renewed interest in Alzheimer's vaccines follows a promising first attempt more than 20 years ago that was abandoned after 6% of study volunteers developed life-threatening brain inflammation known as meningoencephalitis. |
Prothena (PRTA) Pipeline Shows Promise in a Tough AD MarketProthena (PRTA) makes good progress with its AD candidates. However, AD is a challenging space and the successful development of these candidates is crucial. |
Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just BeginningBiogen and Eisai scored key victories in the quest for an Alzheimer's cure. But the race is just getting started. |
Prothena (PRTA) Q3 Earnings Beat on Collaboration Revenue HikeProthena (PRTA) delivers earnings of 38 cents in the third quarter, driven by the license and option exercise fee paid by BMY. |
Prothena Corp PLC (PRTA) Reports Q3 2023 Financial ResultsCompany sees net income of $21.9 million for Q3, receives $55 million payment from Bristol Myers Squibb |
Prothena (PRTA) Beats Q3 Earnings and Revenue EstimatesProthena (PRTA) delivered earnings and revenue surprises of 246.15% and 63.68%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock? |
Prothena Reports Third Quarter 2023 Financial Results and Business HighlightsDUBLIN, November 02, 2023--Prothena today reported financial results for the third quarter and first nine months of 2023 and provided business highlights |
Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out forAxsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Biogen Pulls Prothena Into A Steep Dive On Mixed Results For Alzheimer's TreatmentBiogen stock tumbled Thursday — pulling Prothena stock down — on mixed test results for an updated version of its Alzheimer's treatment. |